中国卫生标准管理
中國衛生標準管理
중국위생표준관리
CHINA HEALTH STANDARD MANAGEMENT
2015年
4期
101-102
,共2页
免疫相关性血小板减少症%利妥昔单抗
免疫相關性血小闆減少癥%利妥昔單抗
면역상관성혈소판감소증%리타석단항
Correlation immune thrombocytopenia%Rituxan
目的评价利妥昔单抗治疗复发难治性免疫相关性血小板减少症的临床疗效及患者的不良反应。方法2例 ITP 患者均明确诊断为ITP,经糖皮质激素、细胞因子等治疗缓解后再次复发,在行利妥昔单抗100 mg/m2,静脉滴注,每周1次,共用4周为1个疗程。结果1例患者因治疗时间长,3周后停药,门诊监测血常规提示患者于2个月后血小板达到75×109/L,1年后患者再次复发。1例患者完成4周治疗,门诊监测血常规是血小板恢复正常,监测至今约 1年,患者未复发。结论利妥昔单抗是治疗复发难治性免疫相关性血小板减少症的有效方法。
目的評價利妥昔單抗治療複髮難治性免疫相關性血小闆減少癥的臨床療效及患者的不良反應。方法2例 ITP 患者均明確診斷為ITP,經糖皮質激素、細胞因子等治療緩解後再次複髮,在行利妥昔單抗100 mg/m2,靜脈滴註,每週1次,共用4週為1箇療程。結果1例患者因治療時間長,3週後停藥,門診鑑測血常規提示患者于2箇月後血小闆達到75×109/L,1年後患者再次複髮。1例患者完成4週治療,門診鑑測血常規是血小闆恢複正常,鑑測至今約 1年,患者未複髮。結論利妥昔單抗是治療複髮難治性免疫相關性血小闆減少癥的有效方法。
목적평개리타석단항치료복발난치성면역상관성혈소판감소증적림상료효급환자적불량반응。방법2례 ITP 환자균명학진단위ITP,경당피질격소、세포인자등치료완해후재차복발,재행리타석단항100 mg/m2,정맥적주,매주1차,공용4주위1개료정。결과1례환자인치료시간장,3주후정약,문진감측혈상규제시환자우2개월후혈소판체도75×109/L,1년후환자재차복발。1례환자완성4주치료,문진감측혈상규시혈소판회복정상,감측지금약 1년,환자미복발。결론리타석단항시치료복발난치성면역상관성혈소판감소증적유효방법。
Objective To evaluate rituxan treatment of recurrence of refractory correlation immune thrombocytopenia in patients with the clinical curative effect and adverse reactions. Methods 2 patients with ITP were clearly diagnosed with ITP, glucocorticoid, cytokines and other treatment to ease after the relapse again, good rituxan 100 mg/m2, intravenous drip, 1 times a week, and Shared 4 weeks for a course of treatment. Results 1 case of patients because of long treatment time, 3 weeks after drug withdrawal, outpatient service monitoring and routine blood platelet after the patients in the two months of 75×109 / L, 1 years patients relapse again. 1 patients completed 4 weeks of treatment, outpatient service monitoring and routine blood platelet is back to normal, monitoring to about 1 year, patients without recurrence. Conclusion Recurrence of rituxan treatment is the effective method of refractory correlation immune thrombocytopenia.